Table 1.
Clinicopathologic features of the 21 cases of gliomatosis peritonei.
| PT |
Age, years |
Ovarian neoplasm |
FIGO stagea |
Metastatic immature teratomab |
Metastatic mature teratomab |
Lymph node status |
GFAP | SOX2 | OCT4 | NANOG | Follow-up durationc |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 18 | Immature teratoma, low-grade | IC2 | No | No | Nodal gliomatosis | + | NA | NA | NA | ANED, 19 months |
| 2 | 29 | Immature teratoma, low-grade | NA | No | No | NA | + | NA | NA | NA | ANED, 2 months |
| 3 | 14 | Immature teratoma, high-grade | NA | Yes | No | NA | + | + | − | − | ANED, 92 months |
| 4 | 15 | Immature teratoma, low-grade | NA | No | Yes | Mature teratoma | NA | + | NA | NA | NA |
| 5 | 19 | Immature teratoma, high-grade | IA | No | Yes | Negative | NA | + | − | − | ANED, 58 months |
| 6d | 13 | Mixed germ cell tumor | IA | No | No | Negative | NA | + | − | − | ANED, 71 month |
| 7d | 36 | Mixed germ cell tumor | NA | Yes | Yes | NA | NA | NA | NA | NA | ADSU, 1 month |
| 8 | 15 | Immature teratoma, high-grade | IA | No | No | NA | NA | + | − | − | ANED, 37 months |
| 9 | 33 | Immature teratoma, low-grade | IA | No | No | NA | NA | NA | NA | NA | ANED, 184 months |
| 10d | 19 | Mixed germ cell tumor | IIIC | Yes | Yes | Negative | NA | + | − | − | ANED, 46 months |
| 11 | 22 | Immature teratoma, high-grade | IA | No | No | Negative | + | NA | NA | NA | ANED, 15 months |
| 12d,e | 40 | Mixed germ cell tumor | IIIC | Yes | No | NA | NA | + | − | − | AWD, 29 months |
| 13d,e | 42 | Mixed germ cell tumor | IIIC | Yes | Yes | Nodal gliomatosis | NA | + | − | − | AWD, 23 months |
| 14 | 5 | Mature cystic teratoma with carcinoid tumor | NA | No | No | NA | + | NA | NA | NA | ANED, 4 months |
| 15e,f | 10 | Immature teratoma, high-grade | NA | Yes | Yes | NA | NA | + | − | − | AWD, 10 months |
| 16d | 10 | Mixed germ cell tumor | NA | No | No | Nodal gliomatosis | NA | NA | NA | NA | ANED, 11 months |
| 17 | 21 | Immature teratoma, high-grade | NA | No | No | NA | NA | NA | NA | NA | NA |
| 18 | 21 | Immature teratoma, high-grade | NA | Yes | No | Negative | NA | NA | NA | NA | NA |
| 19 | 14 | Immature teratoma, low-grade | NA | No | No | NA | NA | NA | NA | NA | NA |
| 20 | 22 | Immature teratoma, high-grade | NA | Yes | Yes | NA | NA | NA | NA | NA | ANED, 5 months |
| 21 | 41 | Immature teratoma, high-grade | NA | Yes | No | IT | NA | NA | NA | NA | ANED, 229 months |
Abbreviations: PT = patient; FIGO = International Federation of Gynecology and Obstetrics; GFAP = glial fibrillary acidic protein; NA = not available; ANED = alive with no evidence of disease; ADSU = alive, disease status unknown; AWD = alive with disease.
International Federation of Gynecology and Obstetrics 2013 Ovarian Cancer Staging System.
Identified at a different anatomic site from that of gliomatosis peritonei.
Duration of follow-up after the diagnosis of primary ovarian neoplasms. Updated on June 2015.
Mixed germ cell tumors were composed of immature teratoma and yolk sac tumor case #6, 13 and 16, and were composed of immature teratoma, yolk sac tumor and embryonal carcinoma in case # 7, 10 and 12.
These three patients were alive with disease according to the follow-up/restaging computed tomography (CT) scan: patient #12 had diffuse peritoneal disease in the subdiaphragmatic regions bilaterally, involving the surfaces of the liver and spleen; patient #13 had multiple peritoneal deposits (the largest measuring 5.0-centimeter in greatest dimension); patient #15 had a mass within the cul-de-sac (approximately 6.0-centimeter).
Patient developed glioma arising from gliomatosis peritonei.